International Journal of Cancer Management

Published by: Kowsar

Effects of Viral Peptide Presentation on CD4+ T Cell Responses to MHC Class II-Restricted Tumor Peptides

Arezoo Gowhari Shabgah 1 , 2 , Jamshid Gholizadeh Navashenaq 1 , 2 , Mir Hadi Seyedzadeh 1 , S A Hamid Moghadasi 3 , Fazel Shokri 1 , Seyed Alireza Razavi 1 and Gholam Ali Kardar 2 , *
Authors Information
1 Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
2 Immunology Asthma and Allergy Research Institute, Tehran University of Medical Sciences, Tehran, Iran
3 Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
Article information
  • International Journal of Cancer Management: June 2017, 10 (6); e8174
  • Published Online: June 30, 2017
  • Article Type: Research Article
  • Received: August 7, 2016
  • Revised: January 3, 2017
  • Accepted: May 13, 2017
  • DOI: 10.5812/ijcm.8174

To Cite: Gowhari Shabgah A, Gholizadeh Navashenaq J, Seyedzadeh M H, Moghadasi S A H, Shokri F, et al. Effects of Viral Peptide Presentation on CD4+ T Cell Responses to MHC Class II-Restricted Tumor Peptides, Int J Cancer Manag. 2017 ; 10(6):e8174. doi: 10.5812/ijcm.8174.

Abstract
Copyright © 2017, International Journal of Cancer Management. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
Footnotes
References
  • 1. Kobayashi H, Celis E. Peptide epitope identification for tumor-reactive CD4 T cells. Curr Opin Immunol. 2008; 20(2): 221-7[DOI][PubMed]
  • 2. Zeng G. MHC class II-restricted tumor antigens recognized by CD4+ T cells: new strategies for cancer vaccine design. J Immunother. 2001; 24(3): 195-204[DOI][PubMed]
  • 3. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med. 1998; 188(12): 2357-68[DOI][PubMed]
  • 4. Noguchi M, Sasada T, Itoh K. Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine. Cancer Immunol Immunother. 2013; 62(5): 919-29[DOI][PubMed]
  • 5. Ait-Tahar K, Liggins AP, Collins GP, Campbell A, Barnardo M, Cabes M, et al. CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma. Haematologica. 2011; 96(1): 78-86[DOI][PubMed]
  • 6. Perez-Diez A, Joncker NT, Choi K, Chan WF, Anderson CC, Lantz O, et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood. 2007; 109(12): 5346-54[DOI][PubMed]
  • 7. Qiu F, Cui Z. CD4+ T helper cell response is required for memory in CD8+ T lymphocytes induced by a poly(I:C)-adjuvanted MHC I-restricted peptide epitope. J Immunother. 2007; 30(2): 180-9[DOI][PubMed]
  • 8. Kitamura H, Sedlik C, Jacquet A, Zaragoza B, Dusseaux M, Premel V, et al. Long peptide vaccination can lead to lethality through CD4+ T cell-mediated cytokine storm. J Immunol. 2010; 185(2): 892-901[DOI][PubMed]
  • 9. Buonaguro L, Petrizzo A, Tornesello ML, Buonaguro FM. Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol. 2011; 18(1): 23-34[DOI][PubMed]
  • 10. Zarour HM, Kirkwood JM, Kierstead LS, Herr W, Brusic V, Slingluff CJ, et al. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc Natl Acad Sci U S A. 2000; 97(1): 400-5[DOI][PubMed]
  • 11. Touloukian CE, Leitner WW, Topalian SL, Li YF, Robbins PF, Rosenberg SA, et al. Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice. J Immunol. 2000; 164(7): 3535-42[DOI][PubMed]
  • 12. Manici S, Sturniolo T, Imro MA, Hammer J, Sinigaglia F, Noppen C, et al. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J Exp Med. 1999; 189(5): 871-6[DOI][PubMed]
  • 13. Jager E, Jager D, Karbach J, Chen YT, Ritter G, Nagata Y, et al. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med. 2000; 191(4): 625-30[DOI][PubMed]
  • 14. Cochlovius B, Stassar M, Christ O, Raddrizzani L, Hammer J, Mytilineos I, et al. In vitro and in vivo induction of a Th cell response toward peptides of the melanoma-associated glycoprotein 100 protein selected by the TEPITOPE program. J Immunol. 2000; 165(8): 4731-41[DOI][PubMed]
  • 15. Schroers R, Shen L, Rollins L, Rooney CM, Slawin K, Sonderstrup G, et al. Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin Cancer Res. 2003; 9(13): 4743-55[PubMed]
  • 16. Castelli FA, Houitte D, Munier G, Szely N, Lecoq A, Briand JP, et al. Immunoprevalence of the CD4+ T-cell response to HIV Tat and Vpr proteins is provided by clustered and disperse epitopes, respectively. Eur J Immunol. 2008; 38(10): 2821-31[DOI][PubMed]
  • 17. Kotsch K, Wehling J, Blasczyk R. Sequencing of HLA class II genes based on the conserved diversity of the non-coding regions: sequencing based typing of HLA-DRB genes. Tissue Antigens. 1999; 53(5): 486-97[DOI][PubMed]
  • 18. Rha SY, Jeung HC, Yang WI, Kim JJ, Oh TJ, An SW, et al. Alteration of hTERT full-length variant expression level showed different gene expression profiles and genomic copy number changes in breast cancer. Oncol Rep. 2006; 15(4): 749-55[DOI][PubMed]
  • 19. Sharma S, Yang SC, Zhu L, Reckamp K, Gardner B, Baratelli F, et al. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res. 2005; 65(12): 5211-20[DOI][PubMed]
  • 20. Takahashi R, Toh U, Iwakuma N, Takenaka M, Otsuka H, Furukawa M, et al. Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients. Breast Cancer Res. 2014; 16(4)[DOI][PubMed]
  • 21. Accolla RS, Tosi G. Optimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells: the key issue for development of anti-tumor vaccines. J Transl Med. 2012; 10: 154[DOI][PubMed]
  • 22. Galaine J, Borg C, Godet Y, Adotevi O. Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine. Vaccines (Basel). 2015; 3(3): 490-502[DOI][PubMed]
  • 23. Buschle M, Schmidt W, Zauner W, Mechtler K, Trska B, Kirlappos H, et al. Transloading of tumor antigen-derived peptides into antigen-presenting cells. Proc Natl Acad Sci U S A. 1997; 94(7): 3256-61[DOI][PubMed]
  • 24. Agur Z, Vuk-Pavlovic S. Personalizing immunotherapy: Balancing predictability and precision. Oncoimmunology. 2012; 1(7): 1169-71[DOI][PubMed]
  • 25. O'Meara MM, Disis ML. Therapeutic cancer vaccines and translating vaccinomics science to the global health clinic: emerging applications toward proof of concept. OMICS. 2011; 15(9): 579-88[DOI][PubMed]
  • 26. Huo LF, Tang JW, Huang JJ, Huang PT, Huang CF, Kung HF, et al. Cancer immunotherapy targeting the telomerase reverse transcriptase. Cell Mol Immunol. 2006; 3(1): 1-11[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments